Correlation of serum N-Acetylneuraminic acid with the risk and prognosis of acute coronary syndrome: a prospective cohort study

Table 3 Risk factors for MACEs in patients with ACS: results of multivariate logistic regression analysis

	B	Sx	Wald	OR (95% CI)	p
Neu5Ac (ng/ml)	0.003	0.001	16.351	1.003 (1.002–1.005)	0.000
Age (years)	0.011	0.011	0.936	1.011 (0.989–1.034)	0.333
Hypertension (%)	0.328	0.234	1.969	0.720 (0.456–1.139)	0.161
Smoking (%)	0.294	0.496	0.351	0.745 (0.282–1.971)	0.553
DM (%)	0.123	0.303	0.165	0.884 (0.488–1.602)	0.684
AF (%)	1.026	0.761	1.182	0.358 (0.081–1.591)	0.177
Previous stroke (%)	0.247	0.435	0.321	0.781 (0.333–1.834)	0.571
FBG (mmol/L)	0.013	0.052	0.059	1.013 (0.915–1.121)	0.807
CRP (mg/L)	0.005	0.007	0.516	1.005 (0.992–1.018)	0.473

MACE Major adverse cardiovascular events, ACS Acute coronary syndrome, OR Odds ratio, CI Confidence interval, Neu5Ac N-acetylneuraminic acid, DM Diabetes mellitus, AF Atrial fibrillation, FBG Fasting blood glucose, CRP C-reactive protein

ISSN: 1471-2261